首页> 外文期刊>Crystal growth & design >In Situ Metastable Form: A Route for the Generation of Hydrate and Anhydrous Forms of Ceritinib
【24h】

In Situ Metastable Form: A Route for the Generation of Hydrate and Anhydrous Forms of Ceritinib

机译:原位亚稳定性形式:用于生成水合物和无水形式的Ceritinib途径

获取原文
获取原文并翻译 | 示例
           

摘要

Ceritinib is an anaplastic lymphoma kinase (ALK) inhibitor used for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC). This BCS class IV drug is developed by Novartis and traded under the name Zykadia. To date two forms [Form A (marketed form) and B] of ceritinib are disclosed in international patent application US 2013/0274279 Al. However, the crystal structure and insight into any solid form of this compound are not available in the literature. In order to achieve better physicochemical properties compared to known solid forms of this compound, novel polymorph identification is chosen as one of the challenging paths to address the issue. In our comprehensive polymorph screening, including in silico and experimental investigations, we discovered three novel solid forms of ceritinib. Out of these three solid forms, two are neat (Form 1 and Form 3) and the remaining one is a hydrate (Form 2). All synthesized forms are further characterized by powder X-ray diffraction, differential scanning calorimetry, and Fourier transform infrared spectroscopy. It is interesting to note that the discovery of this hydrate is in sync with the prediction done using COSMO-RS theory (COSMOthermX software). The current article includes the first single crystal structure of ceritinib Form 1. All forms (Form 1, 2, and 3) of ceritinib are subjected to physicochemical property evaluation like solubility in buffers with a pH range of 1-7, dissolution, and stability. In aqueous solutions and pH 4.5 (acetate buffer), the solubility of Form 2 and 3 is high compared to Form 1, whereas in 0.1 N HCl and 0.01 N HCl Form 1 has a higher solubility compared to Forms 2 and 3. A six-month stability study indicates that all forms (Forms 1, 2, and 3) are stable in ICH stability conditions like accelerated (40 degrees C +/- 2 degrees C, 75% RH +/- 5% RH), long-term (25 degrees C +/- 2 degrees C, 60% RH +/- 5% RH), and low temperature (2-8 degrees C) conditions. A thorough polymorph
机译:Ceritinib是一种促进淋巴瘤激酶(ALK)抑制剂,用于治疗ALK阳性转移性非小细胞肺癌(NSCLC)。该BCS IV类药物是由诺华开发的,并根据Zykadia的名义交易。迄今为止,在国际专利申请美国2013/0274279 A1中披露了Ceritinib的两种形式[表格A(销售形式)和B]。然而,文献中不可用晶体结构和洞察该化合物的任何固体形式。为了获得与已知的该化合物的已知固体形式相比更好的物理化学性质,选择了新的多晶型物鉴定作为解决问题的具有挑战性的路径之一。在我们综合的多晶型筛查中,包括在硅和实验研究中,我们发现了三种新型的Ceritinib。在这三种固体中,两个是整洁的(形式1和形式3),其余的是水合物(形式2)。所有合成的形式都通过粉末X射线衍射,差示扫描量热法和傅里叶变换红外光谱进行了特征。值得注意的是,这种水合物的发现与使用COSMO-RS理论(COSMothermx软件)进行的预测同步。当前制品包括Ceritinib形式的第一单晶结构1. Ceritinib的所有形式(形式1,2和3)经受在pH范围为1-7,溶解和稳定性的缓冲液中的物理化学性质评价。 。在水溶液和pH 4.5(醋酸盐缓冲液)中,与形式1相比,形式2和3的溶解度高,而在0.1N HCl和0.01N HCl形式1中,与形式2和3相比具有更高的溶解度。六 - 月稳定性研究表明,所有形式(形式1,2和3)在加速(40摄氏度+/- 2℃,75%RH +/- 5%RH),长期( 25摄氏度C +/- 2℃,60%RH +/- 5%RH)和低温(2-8℃)条件。彻底的多晶型

著录项

  • 来源
    《Crystal growth & design》 |2017年第12期|共12页
  • 作者单位

    Dr Reddys Labs Ltd Integrated Prod Dev IPDO Ctr Excellence Polymorphism &

    Particle Engn Hyderabad Telangana India;

    Dr Reddys Labs Ltd Integrated Prod Dev IPDO Ctr Excellence Polymorphism &

    Particle Engn Hyderabad Telangana India;

    Dr Reddys Labs Ltd Integrated Prod Dev IPDO Ctr Excellence Polymorphism &

    Particle Engn Hyderabad Telangana India;

    Dr Reddys Labs Ltd Integrated Prod Dev IPDO Ctr Excellence Polymorphism &

    Particle Engn Hyderabad Telangana India;

    Dr Reddys Labs Ltd Integrated Prod Dev IPDO Ctr Excellence Polymorphism &

    Particle Engn Hyderabad Telangana India;

    Dr Reddys Labs Ltd Integrated Prod Dev IPDO Ctr Excellence Polymorphism &

    Particle Engn Hyderabad Telangana India;

    GITAM Univ Coll Sci Dept Chem Visakhapatnam Andhra Pradesh India;

    Dr Reddys Labs Ltd Integrated Prod Dev IPDO Ctr Excellence Polymorphism &

    Particle Engn Hyderabad Telangana India;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 晶体学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号